ViroPharma to Host Investor 'Teach-In' Educational Symposium on Hereditary Angioedema

- Hereditary Angioedema (HAE) and the Dawn of New Therapeutics - EXTON, Pa., March 4 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM ) announced today that the company will provide a live audio webcast of its 'Teach-in' educational event for investors on Hereditary Angioedem...

ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema

EXTON, Pa., Dec. 1 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM ) today announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Cinryze(TM) C1 Inhibitor (human) as a treatment for acute attacks...

ViroPharma Announces Initiation Of Non-Toxigenic Clostridium Difficile Phase 1 Program

...Cinryze(TM) (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information o...

ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomycin Hydorchloride

...Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information o...

ViroPharma Incorporated Reports Second Quarter 2009 Financial Results

... our product used to prevent attacks of hereditary angioedema (HAE) - exceeding our initial expectations, the se...inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for ...

ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009

...Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information o...

Watson Pharmaceuticals Receives a Complete Response Letter for Its 24-Week Formulation of TRELSTAR(R) (triptorelin pamoate) NDA from US FDA

...ncrease in testosterone levels and may initiate or worsen symptoms during this transient period. Rare post-marketing reports of anaphylactic shock and angioedema have been reported. TRELSTAR(R) is contraindicated for use in women. About Watson Pharmaceuticals, Inc. Watson Pharmaceuticals, Inc., i...

Changing Paradigms in Hereditary Angioedema: A Focus on Timely Diagnosis and New Therapies

... VOORHEES, N.J., July 9 /PRNewswire/ -- Hereditary angioedema (HAE) is an autosomal dominant disease affecting approximately 10,000 people in the United States. HAE causes recurrent attacks of intense localized e...

Changing Paradigms in Hereditary Angioedema: Pathophysiology, Diagnosis and Treatment

... Complimentary Continuing Education Monograph for Healthcare Professionals VOORHEES, N.J., June 29 /PRNewswire/ -- Hereditary angioedema (HAE) is an autosomal dominant disease affecting between 4,000 and 10,000 people in the United States. HAE causes recurrent attacks of intense localiz...

New Directions in Angioedema: A Focus on Etiologies and Clinical Approach

...onals VOORHEES, N.J., June 10 /PRNewswire/ -- angioedema is a clinical syndrome characterized by localized,...cosal swelling. Diagnosing the underlying cause of angioedema can be challenging, as there are multiple etiologi...cation newsletter series titled New Directions in angioedema . The second issue of this three-part newsletter s...

Angioedema in Medical Technology

FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)

- PDUFA Date for Cinryze for Acute HAE Indication is June 3, 2009 - EXTON, Pa., Feb. 3 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM ) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for Cinryze C1 Inhibitor (human) as a trea...

ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema

- New Data from Open Label Study and New Data Suggesting Need for Improved HAE Screening Presented at ACAAI 2008 Annual Meeting - EXTON, Pa., Nov. 12 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM ) today announced the presentation of data from its ongoing, open-label ...

CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema

Pivotal phase II/III study demonstrates C1-INH is effective treatment for acute HAE attacks KING OF PRUSSIA, Pa., March 6 /PRNewswire/ -- CSL Behring has submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) requesting approval ...

CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema

KING OF PRUSSIA, Pa., Nov. 26 /PRNewswire/ -- CSL Behring announced today that it has reached the primary endpoint of a Phase III clinical trial of human pasteurized C1-inhibitor (C1-INH) concentrate to treat patients with hereditary angioedema (HAE), a rare genetic disorder that can lead to p...

DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial (EDEMA3)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 12, 2007 - Dyax Corp. (Nasdaq:DYAX) announced today positive topline results from its Phase 3, placebo-controlled trial, EDEMA3, for its lead product candidate DX-88 (ecallantide), for hereditary angioedema (HAE). A webcast presentation of the EDEMA3 data is s...

Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III Trial for Hereditary Angioedema

Company anticipates second quarter BLA filing for C1-inhibitor replacement therapy NEW YORK, March 14, 2007 /PRNewswire-FirstCall/ -- Lev Pharmaceuticals, Inc. (Lev) today announced positive results from its pivotal U.S. Phase III trial of C1-esterase inhibitor (C1-INH) for the acute treatment of ...

Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema

NEW YORK, May 31, 2007 /PRNewswire-FirstCall/ -- Lev Pharmaceuticals, Inc. ("Lev" or the "Company") announced today that it has completed patient treatment in the prophylactic portion of its Phase III clinical trial of C1-esterase inhibitor (C1-INH) for hereditary angioedema (HAE). The clinical tr...

Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop

...er 2008 for routine prophylaxis against hereditary angioedema (HAE) attacks in adults and adolescents. In Februa... Prophylactic Therapy Considerations in Hereditary angioedema In an abstract entitled, 'When ...C1 Inhibitor as Therapy for Swelling in Hereditary angioedema Patients Reverses Abnormalities of the Plasma Brad...

ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance

...ins, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information o...

Changing Paradigms in Hereditary Angioedema: A Focus on Prompt Diagnosis and New Therapies

... Complimentary Continuing Education Lecture for Healthcare Professionals VOORHEES, N.J., March 17 /PRNewswire/ -- Hereditary angioedema (HAE) is estimated to afflict 10,000 people in the United States each year. Patients with HAE suffer from recurrent attacks of intense localized edema...

Angioedema in Medical Dictionary

Angioedema

Angioedema is the rapid swelling (edema) of the dermis, subcutaneous tissue, mucosa and submucosal tissues. It is very similar to urticaria, but urticaria, commonly known as hives, occurs in the upper dermis. Angioedema , Angioedema refers to swelling that occurs in the ... Both h...

Hereditary angioedema

Angioedema is the rapid swelling (edema) of the dermis, subcutaneous tissue, mucosa and submucosal tissues. It is very similar to urticaria, but urticaria, commonly known as hives, occurs in the upper dermis. Hereditary angioedema (HAE) is caused by low levels or improper function o...

Urticaria

...ue to certain foods and additives, medications, ... Foods such as eggs, nuts and shellfish are common causes of urticaria . ... Urticaria , angioedema (hives). Authoritative facts about the skin from the New Zealand Dermatological Society. ... Urticaria provoked by aspirin and other non ... ...

Hives

...ent stories, diagnostic guides, medical books excerpts online about Hives , 202 drug side effect causes, 71 drug interaction ... Hives and angioedema — Comprehensive overview covers symptoms, causes, treatment of these ... Hives — also known as urticaria (ur-tih-KAR-e-uh) — are ... Urtica...

Angioedema in Biological Technology

ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema

- Company Also Granted Expansion of Prophylaxis Therapy Label to Include Patient Labeling for Self-Administration - EXTON, Pa., June 4 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM ) today announced that it has received a Complete Response letter from the U.S. Food and Dr...

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

...e of charge initially, in order to provide access to patients as quickly as possible. FIRAZYR(R) - for the treatment of hereditary angioedema ("HAE") - In June 2009, Shire initiated a Phase 3 study in patients with acute attacks of HAE, known as the FAST-3 trial, which is designed to ...

ViroPharma to Present at Two June Healthcare Conferences

...Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information o...

ViroPharma Incorporated Honored by the National Organization for Rare Disorders

... for a rare and devastating disorder -- hereditary angioedema (HAE). HAE is a rare, severely debilitating, ...en approved by FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE.... every 3 or 4 days for routine prophylaxis against angioedema attacks in HAE patients. Cinryze is administered ...

Shire begins the year with a strong performance

...e colitis in certain EU countries during 2009; - FIRAZYR(R) (icatibant) for the symptomatic treatment of acute attacks of herediatary angioedema ("HAE") in certain European and Latin American countries during 2009; - INTUNIV for the treatment of ADHD in children and adolescents in th...

ViroPharma Incorporated Reports First Quarter 2009 Financial Results

...Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information o...

ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009

...ins, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information o...

Publication of Shire plc's Annual Report 2008

... Pharmaceuticals area. Human Genetic Therapies Treatments for angioedema FIRAZYR for hereditary angioedema ('HAE') in the US FIRAZYR is a treatment for acute HAE which Shire a...

ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes

...ins, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information o...

ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results

...h of Cinryze for routine prophylaxis of hereditary angioedema (HAE); Developed and successfully launched...inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for ...